CLINICAL TRIALS PROFILE FOR DACTINOMYCIN

All Clinical Trials for dactinomycin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002489 ↗	Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors	Completed	Memorial Sloan Kettering Cancer Center	Phase 2	1991-10-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating children who have non-testicular malignant germ cell tumors.
NCT00002516 ↗	Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma	Unknown status	Medical Research Council	Phase 3	1992-07-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug with surgery and radiation therapy may kill more tumor cells. It is not yet known which combination chemotherapy regimen is most effective in treating patients with Ewing's sarcoma. PURPOSE: Randomized phase III trial to compare various combination chemotherapy regimens plus surgery and radiation therapy in treating patients who have Ewing's sarcoma.
NCT00002516 ↗	Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma	Unknown status	University Hospital Muenster	Phase 3	1992-07-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug with surgery and radiation therapy may kill more tumor cells. It is not yet known which combination chemotherapy regimen is most effective in treating patients with Ewing's sarcoma. PURPOSE: Randomized phase III trial to compare various combination chemotherapy regimens plus surgery and radiation therapy in treating patients who have Ewing's sarcoma.
NCT00002610 ↗	Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors	Completed	National Cancer Institute (NCI)	Phase 3	1996-01-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known which therapy regimen is most effective for treating patients with kidney tumors. PURPOSE: Phase III trial to compare the effectiveness of chemotherapy with or without radiation therapy, surgery, and/or peripheral stem cell or bone marrow transplantation in treating young patients with kidney tumors.
NCT00002610 ↗	Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors	Completed	Children's Oncology Group	Phase 3	1996-01-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known which therapy regimen is most effective for treating patients with kidney tumors. PURPOSE: Phase III trial to compare the effectiveness of chemotherapy with or without radiation therapy, surgery, and/or peripheral stem cell or bone marrow transplantation in treating young patients with kidney tumors.
NCT00002611 ↗	Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer	Completed	National Cancer Institute (NCI)	Phase 3	1995-07-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. It is not yet known whether combination chemotherapy alone or combination chemotherapy plus radiation therapy is more effective for childhood kidney cancer. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy with or without radiation therapy in treating children who have kidney cancer.
NCT00002611 ↗	Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer	Completed	Children's Oncology Group	Phase 3	1995-07-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. It is not yet known whether combination chemotherapy alone or combination chemotherapy plus radiation therapy is more effective for childhood kidney cancer. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy with or without radiation therapy in treating children who have kidney cancer.

Clinical Trial Conditions for dactinomycin

Condition Name

Condition Name for dactinomycin
Intervention	Trials
Sarcoma	13
Kidney Cancer	5
Rhabdomyosarcoma	5
Adult Rhabdomyosarcoma	4

Condition MeSH

Condition MeSH for dactinomycin
Intervention	Trials
Rhabdomyosarcoma	18
Sarcoma	16
Wilms Tumor	10
Rhabdomyosarcoma, Embryonal	7

Clinical Trial Locations for dactinomycin

Trials by Country

Trials by Country for dactinomycin
Location	Trials
United States	841
Canada	128
Australia	66
Japan	49
New Zealand	19

Trials by US State

Trials by US State for dactinomycin
Location	Trials
California	24
New York	24
Texas	24
Pennsylvania	22
Ohio	22

Clinical Trial Progress for dactinomycin

Clinical Trial Phase

Clinical Trial Phase for dactinomycin
Clinical Trial Phase	Trials
PHASE3	2
PHASE2	1
Phase 4	1

Clinical Trial Status

Clinical Trial Status for dactinomycin
Clinical Trial Phase	Trials
Completed	19
Unknown status	11
Recruiting	8

Clinical Trial Sponsors for dactinomycin

Sponsor Name

Sponsor Name for dactinomycin
Sponsor	Trials
National Cancer Institute (NCI)	24
Children's Oncology Group	18
Children's Cancer and Leukaemia Group	5

Sponsor Type

Sponsor Type for dactinomycin
Sponsor	Trials
Other	66
NIH	24
Industry	2

Clinical Trials Update, Market Analysis, and Projection for Dactinomycin

Last updated: October 28, 2025

---

Introduction

Dactinomycin, also known as actinomycin D, is a potent chemotherapy agent primarily utilized in the treatment of various malignancies, including pediatric Wilms' tumor, rhabdomyosarcoma, Ewing's sarcoma, and gestational trophoblastic neoplasia. Its unique mechanism of intercalating DNA and inhibiting RNA synthesis has cemented its role in oncologic therapeutics. This article offers a comprehensive overview of current clinical trials, market dynamics, and future projections for Dactinomycin, emphasizing strategic insights for stakeholders.

---

Clinical Trials Landscape for Dactinomycin

Current Clinical Trials and Therapeutic Indications

As of 2023, Dactinomycin remains a mainstay in pediatric oncology, with ongoing studies exploring expanded indications and combination therapies. The National Cancer Institute (NCI) database lists approximately 15 active or recruiting clinical trials investigating Dactinomycin, primarily focusing on:

• Rare pediatric tumors: Trials aim to evaluate efficacy in atypical sarcomas and refractory cases.
• Combination regimens: Research is underway assessing Dactinomycin plus newer agents like immune checkpoint inhibitors and targeted therapies to enhance therapeutic outcomes.
• Alternative formulations: Several studies examine liposomal and nanoparticle delivery systems to improve pharmacokinetics and reduce toxicity.

Emerging Research and Innovation

Recent advances include:

• Biomarker-driven approaches: Efforts to identify molecular markers predictive of response to Dactinomycin.
• Immunomodulation: Investigating Dactinomycin's potential to induce immunogenic cell death, thereby synergizing with immunotherapies.
• Dose optimization studies: Aiming to minimize adverse effects while maintaining efficacy, particularly in combination protocols.

Barriers in Clinical Development

Despite ongoing research, challenges include:

• Toxicity concerns: Myelosuppression, mucositis, and gonadal toxicity limit dosing, especially in pediatric populations.
• Resistance mechanisms: Tumor cells develop efflux pump-mediated resistance, reducing effectiveness.
• Limited commercial incentives: Since Dactinomycin's patent has expired, investment in novel formulations or indications is constrained, impacting trial funding.

---

Market Analysis

Historical Market Overview

Dactinomycin has historical roots dating back to its first FDA approval in 1961. The traditional market has been predominantly driven by pediatric oncology needs. The global market was valued at approximately USD 85 million in 2022, with steady growth due to its established use in specific cancers.

Market Drivers and Constraints

Drivers:

• Pediatric oncology demand: The rarity yet high volume in childhood cancers sustains steady consumption.
• Shift towards combination regimens: Incorporation into multi-agent protocols enhances treatment efficacy.
• Emerging use in adult tumors: Exploratory studies could broaden applications, opening new markets.

Constraints:

• Toxicity profiles: Toxic adverse effects and the narrow therapeutic window limit broader adoption.
• Generic availability: As a generic drug, profit margins for manufacturers are reduced, dampening investment into R&D.
• Market competition: Alternative therapies with improved safety profiles and targeted mechanisms threaten market share.

Regional Market Dynamics

• North America: Dominates due to established healthcare infrastructure and high pediatric cancer prevalence.
• Europe: Similar trends with increased clinical trials aiming to validate new combinations.
• Asia-Pacific: Growing efficacy awareness and expanding pediatric oncology programs suggest increasing demand, though access to older chemotherapeutics remains variable.

---

Market Projection and Future Outlook

Forecast Period: 2023-2030

The global Dactinomycin market is projected to experience a compound annual growth rate (CAGR) of approximately 4.5% over the next decade. Key factors influencing this projection include:

• Emerging clinical evidence: Positive trial outcomes demonstrating efficacy in resistant or relapsed cancers may lead to label expansions.
• Regulatory developments: Potential USFDA or EMA approvals for novel indications or formulations could catalyze market growth.
• Technological advancements: Development of targeted delivery systems promises to mitigate toxicity, broadening applicability.

Potential Market Opportunities

• Expanded pediatric indications: Confirmatory studies supporting use in additional tumor types could expand use.
• Adult oncology: Repurposing for adult cancers, especially those with limited treatment options, presents a significant opportunity.
• Partnerships and licensing: Collaborations with biotech firms to develop next-generation formulations could stimulate growth.
• Emerging markets: Increased healthcare infrastructure in developing regions offers growth potential, contingent on affordability and supply chains.

Risks to Market Growth

• Competitive landscape: Novel targeted agents may supersede Dactinomycin’s use.
• Regulatory hurdles: Delays in trial approvals or regulatory revisions could impede market expansion.
• Pricing pressures: Cost containment policies might reduce profit margins for manufacturers.

---

Strategic Implications for Stakeholders

For pharmaceutical companies, investment in formulation innovation and clinical validation is pivotal. Academic institutions and research organizations should foster collaborative trials to expand indications. Policymakers and payers will influence market access through reimbursement policies, especially for newer formulations or expanded use cases.

---

Key Takeaways

• Dactinomycin remains integral to pediatric oncology; ongoing clinical trials explore new combinations and delivery systems.
• Market growth is expected to be modest but steady, driven by expanding indications and technological improvements.
• Commercial opportunities include formulation enhancements, adult oncology applications, and emerging markets.
• Challenges such as toxicity, resistance, and limited profitability hinder rapid innovation but can be mitigated through targeted research.
• Regulatory and reimbursement landscape will significantly influence market trajectory and adoption.

---

Conclusion

Dactinomycin’s enduring role in cancer therapy underscores its therapeutic value, but continued innovation and strategic market positioning are essential for future growth. Stakeholders must navigate clinical, regulatory, and competitive landscapes carefully to capitalize on emerging opportunities. With advances in formulation technology and expanding clinical evidence, Dactinomycin’s market outlook remains cautiously optimistic, emphasizing the importance of sustained R&D investment.

---

FAQs

1. What are the primary indications for Dactinomycin today?
Dactinomycin is predominantly used in pediatric cancers such as Wilms' tumor, rhabdomyosarcoma, and gestational trophoblastic neoplasia, with some off-label applications in refractory adult cancers under research.

2. Are there ongoing efforts to develop new formulations of Dactinomycin?
Yes, research focuses on liposomal and nanoparticle formulations aimed at reducing toxicity, enhancing delivery, and expanding therapeutic windows.

3. How does the toxicity profile impact Dactinomycin’s clinical use?
Its adverse effects, including myelosuppression and mucositis, necessitate careful dose management, especially in children, which can limit broader application.

4. Is Dactinomycin being evaluated for novel cancer indications?
Yes, current trials are exploring its utility in resistant sarcomas, combination regimens with immunotherapies, and possibly, adult cancers.

5. What are the prospects of market expansion for Dactinomycin?
Expansion hinges on clinical validation for new indications, development of safer formulations, and regulatory approvals, with emerging markets representing additional growth opportunities.

---

References

[1] National Cancer Institute. Clinical Trials Database. Accessed 2023.
[2] Grand View Research. Chemotherapy Drugs Market Analysis, 2022.
[3] U.S. Food and Drug Administration. Drug Approvals and Labeling.
[4] Saini, S., & Sharma, L. (2021). Advances in Dactinomycin Formulations. Journal of Oncology Pharmacy Practice.
[5] MarketWatch. Oncology Drugs Market Trends & Forecasts, 2023-2030.